查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球Peptide治疗市场和临床试验考虑因素（2028 年）
市场调查报告书
商品编码
1071378

全球Peptide治疗市场和临床试验考虑因素（2028 年）

Global Peptide Therapeutics Market & Clinical Trials Insight 2028
出版日期: | 出版商: PNS Pharma | 英文 1200 Pages | 商品交期: 最快1-2个工作天内

价格

到2028年，全球Peptide药物市场预计将达到750亿美元。目前，超过 800 种Peptide治疗药物处于临床试验阶段，超过 200 种已上市。

按指标，抗癌□占据全球市场份额的 25% 以上。

本报告分析了全球Peptide治疗药物市场的临床试验趋势，并按产品类型（按公司/适应症）提供了产品概述、市场增长前景、整体临床试验概况和临床试验进展。将为您提供诸如（按疾病/阶段）、主要公司概况和竞争情况等信息。

目录

第 1 章□疗法：概述

  • Peptide疗法概述
  • □疗法的历史展望
  • 抗癌□的分类

第二章治疗性□的靶点

  • 信号转导通路
  • 细胞週期调控
  • 细胞死亡途径
  • 抑癌蛋白
  • 转录因子

第 3 章全球□治疗市场：概述

第4章世界Peptide治疗药物：临床试验综述

  • 按公司
  • 按国家/地区
  • 按指示
  • 按患者细分
  • 按阶段（按阶段）

第 5 章胰岛素临床管道：按公司/适应症/阶段

  • 研究
  • 临床前
  • 第一阶段
  • 第二阶段
  • 二期/三期
  • 第三阶段
  • 已应用
  • 已批准
  • 推出

第6章胰高血糖素样□临床管线：按公司、按适应症、按阶段

第7章□临床管道：按公司/适应症/阶段

第8章环□临床管道：按公司/适应症/阶段

第9章Peptide临床管线：按公司/适应症/阶段

第10章糖□临床管线：按公司/适应症/阶段

第11章寡□临床管道：按公司/适应症/阶段

第12章脂□临床管线：按公司、按适应症、按阶段

第13章二□临床管道：按公司/适应症/阶段

第14章阿片□临床管道：按公司/适应症/阶段

第 15 章 Depsipeptide 临床管道：按公司/适应症/阶段

第16章神经□临床管线：按公司、按适应症、按阶段

第17章利钠□临床管线：按公司/适应症/阶段

第18章双环□临床管线：按公司/适应症/阶段

第19章竞争态势

  • Amgen
  • Amylin Pharmaceuticals
  • Apitope Technology
  • BioPartners
  • BiondVax Pharmaceuticals Ltd
  • Boehringer Ingelheim
  • Circassia
  • Corden Pharma (Peptisyntha)
  • Eli Lily
  • Galena Biopharmaceuticals
  • GlaxoSmithKline
  • Hyperion Therapeutics
  • ImmunoCellular Therapeutics
  • Ipsen
  • Lonza
  • Merck
  • NovoNordisk
  • Par Pharmaceuticals
  • PeptiDream
  • Roche
  • Sanofi
  • Tarix Pharmaceuticals

“Global Peptide Therapeutics Market & Clinical Trials Insight 2028” Report findings:

  • Global Peptide Therapeutics Market Opportunity > USD 75 billion by 2028
  • Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
  • Peptide Therapeutics in Clinical trials: > 800 Drugs
  • Peptide Therapeutics Commercially Available In Market: > 200 Drugs
  • Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides

Peptides are naturally occurring, small biological molecules made of short chains of amino acids linked by a peptide bond, performing multiple functions within the cell. Peptide drugs have been in use for almost a century now, though initially they were only used to replicate the action of natural hormones for metabolic diseases, for example, the first of this kind that was approved for clinical usage was insulin for the management of diabetes. However, decades of research and development of peptides have resulted in the discovery of peptides that have the ability to penetrate the cell with advanced actions, all of which have shown excellent results for various therapeutic functions.

Till date, more than 200 peptide based therapeutics have gained approval from regulatory bodies. The most common indications for peptides are oncology, endocrinology, and metabolic diseases. Other target areas of peptides that have gained attention include gastroenterology, cardiovascular diseases, dermatology, bone diseases, and sexual dysfunction. The robust response of peptide therapeutics in the market has propelled the further research activities in this domain. Currently, more than 800 clinical trials are ongoing in global peptide therapeutics market which suggests promising future of peptide therapeutics in the forthcoming years.

The global peptide therapeutics market is both competitive along with being fragmented on account of the presence of several international and also domestic industry players. Such industry players have utilized an assorted innovative strategies for being at the top along with sufficing to the burgeoning requirement of the esteemed clients including geographic expansions, collaborations, joint ventures, new product launches, partnerships, contracts, and much more. For instance, Bicycle Therapeutics has entered into strategic collaboration with Genentech to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Further, Fusion Pharmaceuticals also enter into collaboration with Pepscan to discover, novel, peptide-based radiopharmaceuticals for the management of solid tumors.

By therapeutic indication, cancer peptide occupies more than 25% share in the global market. Several peptide based drugs including Firmagon, Eligard, Velcade, Zoladex, Cosmegen, Sandostatin, Mepact, and others have entered the market and have shown robust response rate. More recently, peptide cancer vaccine namely Riavax have also gained approval in South Korea for the treatment of locally advanced or metastatic pancreatic cancer. The promising sales of these drugs are driving this segment during the forecast period. Furthermore, surge in prevalence of cancer and unmet need of cost effective targeted drugs are also anticipated to propel the growth of cancer peptide drugs during the forecast period.

It is analyzed that the future holds an extensive place for peptides in addressing the greatest of medical challenge due to their capability of being adapted and modified to achieve the desired action. There is immense scope for the development of new peptides with protein fragmentation along with alternative routes of administration and improved oral bioavailability. They will also be used to address the currently undruggable targets in the coming years. Keeping the clinical pipeline in consideration, it is expected that the global peptide therapeutics market will surpass US$ 75 Billion by 2028. In addition to above mentioned factors, rising geriatric population and associated increase in chronic disease will also drive the growth of market.

The report provides detailed review of the overall market landscape of peptide-based therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of peptide, route of administration, and key therapeutic area. The report also gives insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules. This report forecasts revenue growth at global levels and provides an analysis of the latest trends and opportunities. The major companies mentioned in the report include Amgen, GlaxoSmithKline, NovoNordisk, ImmunoCellular Therapeutics, Lonza, PeptiDream and others.

Table of Contents

1. Introduction to Peptide Therapeutics

  • 1.1. Overview of Peptide Therapeutics
  • 1.2. Historical Perspective of Peptide Therapeutics
  • 1.3. Classification Of Anti Cancer Peptides

2. Targets for Therapeutic Peptides

  • 2.1. Signal Transduction Pathways
  • 2.2. Cell Cycle Regulation
  • 2.3. Cell Death Pathways
  • 2.4. Tumor Suppressor Protein
  • 2.5. Transcription Factors

3. Global Peptide Therapeutics Market Overview

4. Global Peptide Therapeutics Clinical Trials Overview

  • 4.1. By Company
  • 4.2. By Country
  • 4.3. By Indication
  • 4.4. By Patient Segment
  • 4.5. By Phase

5. Insulin Clinical Pipeline By Company, Indication & Phase

  • 5.1. Research
  • 5.2. Preclinical
  • 5.3. Phase-I
  • 5.4. Phase-II
  • 5.5. Phase-II/III
  • 5.6. Phase-III
  • 5.7. Preregistration
  • 5.8. Registered
  • 5.9. Marketed

6. Glucagon-like Peptides Clinical Pipeline By Company, Indication & Phase

  • 6.1. Research
  • 6.2. Preclinical
  • 6.3. Phase-I
  • 6.4. Phase-I/II
  • 6.5. Phase-II
  • 6.6. Phase-III
  • 6.7. Preregistration
  • 6.8. Marketed

7. Peptides Clinical Pipeline By Company, Indication & Phase

  • 7.1. Research
  • 7.2. Preclinical
  • 7.3. Clinical Phase Unknown
  • 7.4. Phase-I
  • 7.5. Phase-I/II
  • 7.6. Phase-II
  • 7.7. Phase-II/III
  • 7.8. Phase-III
  • 7.9. Preregistration
  • 7.12. Registered
  • 7.11. Marketed

8. Cyclic Peptides Clinical Pipeline By Company, Indication & Phase

  • 8.1. Research
  • 8.2. Preclinical
  • 8.3. Clinical Phase Unknown
  • 8.4. Phase-I
  • 8.5. Phase-II
  • 8.6. Phase-III
  • 8.7. Marketed

9. Multiple Peptides Clinical Pipeline By Company, Indication & Phase

  • 9.1. Research
  • 9.2. Preclinical
  • 9.3. Phase-I
  • 9.4. Phase-I/II
  • 9.5. Phase-II
  • 9.6. Phase-III
  • 9.7. Preregistration
  • 9.8. Registered
  • 9.9. Marketed

10. Glycopeptides Clinical Pipeline By Company, Indication & Phase

  • 10.1. Research
  • 10.2. Preclinical
  • 10.3. Phase-I
  • 10.4. Phase-I/II
  • 10.5. Preregistration
  • 10.6. Marketed

11. Oligopeptides Clinical Pipeline By Company, Indication & Phase

  • 11.1. Preclinical
  • 11.2. Phase-I/II
  • 11.3. Phase-II
  • 11.4. Phase-II/III
  • 11.5. Phase-III
  • 11.6. Registered
  • 11.7. Marketed

12. Lipopeptides Clinical Pipeline By Company, Indication & Phase

  • 12.1. Research
  • 12.2. Phase-II
  • 12.3. Marketed

13. Dipeptides Clinical Pipeline By Company, Indication & Phase

  • 13.1. Research
  • 13.2. Phase-I
  • 13.3. Phase-II
  • 13.4. Phase-III
  • 13.5. Registered
  • 13.6. Marketed

14. Opioid Peptides Clinical Pipeline By Company, Indication & Phase

  • 14.1. Research
  • 14.2. Preclinical
  • 14.3. Phase-I/II
  • 14.4. Preregistration
  • 14.5. Registered
  • 14.6. Marketed

15. Depsipeptides Clinical Pipeline By Company, Indication & Phase

  • 15.1. Preclinical
  • 15.2. Phase-II
  • 15.3. Registered
  • 15.4. Marketed

16. Neuropeptides Clinical Pipeline By Company, Indication & Phase

  • 16.1. Research
  • 16.2. Preclinical
  • 16.3. Phase-I/II
  • 16.4. Phase-II
  • 16.5. Marketed

17. Natriuretic Peptides Clinical Pipeline By Company, Indication & Phase

  • 17.1. Phase-II
  • 17.2. Marketed

18. Bicyclic Peptides Clinical Pipeline By Company, Indication & Phase

  • 18.1. Preclinical

19. Competitive Landscape

  • 19.1. Amgen
  • 19.2. Amylin Pharmaceuticals
  • 19.3. Apitope Technology
  • 19.4. BioPartners
  • 19.5. BiondVax Pharmaceuticals Ltd
  • 19.6. Boehringer Ingelheim
  • 19.7. Circassia
  • 19.8. Corden Pharma (Peptisyntha)
  • 19.9. Eli Lily
  • 19.10. Galena Biopharmaceuticals
  • 19.11. GlaxoSmithKline
  • 19.12. Hyperion Therapeutics
  • 19.13. ImmunoCellular Therapeutics
  • 19.14. Ipsen
  • 19.15. Lonza
  • 19.16. Merck
  • 19.17. NovoNordisk
  • 19.18. Par Pharmaceuticals
  • 19.19. PeptiDream
  • 19.20. Roche
  • 19.21. Sanofi
  • 19.22. Tarix Pharmaceuticals

List of Figures

  • Figure 1-1: Classification of Anti-Cancer Peptides
  • Figure 2-1: Therapeutic Peptides Based on Their Biological Targets
  • Figure 2-2: MAPK Signaling Pathways
  • Figure 2-3: Cell Cycle in Eukaryotic
  • Figure 2-4: Cell Death Pathways
  • Figure 2-5: Features of Bcl-2 Family Proteins Including Anti-Apoptotic & Pro-Apoptotic
  • Figure 3-1: Global - Peptide Therapeutic Market (US$ Billion), 2020 - 2028
  • Figure 3-2: Global - Total Peptide Therapeutic Market Size vs. Cancer Peptide Therapeutic Market (US$ Billion), 2021
  • Figure 3-3: Global - Cancer Peptide Market Share in Total Peptide Market (%), 2021
  • Figure 3-4: Global - Cancer Peptide Drugs Market Size (US$ Billion), 2020 - 2028
  • Figure 4-1: Global - Peptide Drug Clinical Pipeline by Company (Number of Drugs), 2022 till 2028
  • Figure 4-2: Global - Peptide Drug Clinical Pipeline by Country (Number of Drugs), 2022 till 2028
  • Figure 4-3: Global - Peptide Drug Clinical Pipeline by Indication (Number of Drugs), 2022 till 2028
  • Figure 4-4: Global - Peptide Drug Clinical Pipeline by Patient Segment (Number of Drugs), 2022 till 2028
  • Figure 4-5: Global - Peptide Drug Clinical Pipeline by Phase (Number of Drugs), 2022 till 2028